Exclusive: Kimia Therapeutics secures $55M to supercharge co-founder’s platform, create ‘next-generation Carmot’
Stig Hansen and his team are looking to replicate the success they had with Carmot Therapeutics, but under a different name with the same meaning in another language and a “supercharged” approach to their drug discovery platform.
Hansen spun out Kimia Therapeutics and brought a handful of employees with him in January after co-founding and leading Carmot for nearly 15 years. Carmot’s platform helped lay the foundation to develop Amgen’s cancer drug Lumakras, and then the company molded its internal pipeline into clinical-stage obesity and diabetes drug candidates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.